B cell depletion improves therapeutic index of combination checkpoint blockade in patients with advanced melanoma
Journal of Clinical Investigation · 02.11.2026 · 136 (21)
DOI: 10.1172/jci205606 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Investigation, online erschienen am 25.08.2026. Verfasst von Kavita M Dhodapkar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Melanoma, Rituximab, B-Lymphocytes, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
BACKGROUND Combined checkpoint blockade (CCB) of programmed-death–1 (PD-1) and cytotoxic-T-lymphocyte–associated protein-4 (CTLA-4) is highly active in melanoma but limited by significant morbidity from immune-related adverse events (irAEs). Effective strategies to prevent CCB-mediated irAEs are lacking. METHODS Patients with advanced melanoma were randomly assigned to receive standard of care ipilimumab and nivolumab alone (Arm A: ipi/nivo, n = 7) or with one cycle of rituximab (Arm B; ipi/nivo+rituximab, n = 7). RESULTS Patients receiving ipi/nivo+rituximab experienced lower rates of greater than grade-3(G3) irAEs (14% versus 57%) and superior G3-irAE–free survival compared with those in ipi/nivo arm (2-year G3-irAE-free survival 86% versus 29%, P = 0.01), without adverse impact on tumor regression or survival. G3 hypersensitivity reactions to rituximab (43% in Arm B) prompted trial closure. Rituximab depleted pretherapy activated naive B cells linked to autoimmunity and enhanced CCB-mediated induction of myeloid inflammation and CXCL13 + ICOS + CD4 T cells. CONCLUSION B cell depletion favorably modulates CCB-mediated immune activation and may reduce irAE risk. TRIAL REGISTRATION ClinicalTrials.gov NCT03719131. FUNDING NIH CA238471, AR077926, CA289978, and CA290302.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Seattle Children's Hospital, Seattle, Washington, USA.
- Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Förderung
- NIAMS NIH HHS
- NCI NIH HHS
- National Cancer Institute
- NIH
Zitieren
APA
Dhodapkar, K. M., Matera, A., Duffy, A. M., Taz, A., Manalo, R. J., Yushak, M., Kudchadkar, R., Lawson, D. H., & Dhodapkar, M. V. (2026). B cell depletion improves therapeutic index of combination checkpoint blockade in patients with advanced melanoma. Journal of Clinical Investigation, 136(21). https://doi.org/10.1172/jci205606
Vancouver
Dhodapkar KM, Matera A, Duffy AM, Taz A, Manalo RJ, Yushak M, et al. B cell depletion improves therapeutic index of combination checkpoint blockade in patients with advanced melanoma. Journal of Clinical Investigation. 2026;136(21). doi:10.1172/jci205606
BibTeX
@article{Dhodapkar2026,
author = {Dhodapkar, Kavita M and Matera, Antonio and Duffy, Alyssa M and Taz, Azmain and Manalo, Renee Julia and Yushak, Melinda and Kudchadkar, Ragini and Lawson, David H and Dhodapkar, Madhav V},
title = {B cell depletion improves therapeutic index of combination checkpoint blockade in patients with advanced melanoma},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {21},
doi = {10.1172/jci205606}
}
EUVIMED